Active, not recruiting
Not applicable
A Clinical Trial to Evaluate the Effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in Adults With Eczema-Prone Skin
Condition(s) studied
EczemaAtopic DermatitisEczema-Prone Skin
Investigational drug(s) / intervention(s)
Rejuvaskin Eczema Body Wash
Rejuvaskin Eczema Body Wash: Participants use Rejuvaskin Eczema Body Wash once daily during a shower or bath in place of their usual body cleanser, followed by application of Rejuvaskin Skin Recovery Cream, for 4 consecutive weeks.
Study summary
This is a single-arm, open-label, decentralized (fully remote) clinical trial evaluating the tolerability and self-perceived skin effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in 35 adults aged 18-65 with self-reported eczema-prone skin. Participants will use the body wash once daily in place of their usual cleanser, followed by the Skin Recovery Cream, for 4 consecutive weeks.
Eligibility
Inclusion Criteria:
* Adult women or men aged 18-65 years.
* Self-reported symptoms of eczema or eczema-prone skin (e.g., dryness, roughness, itching, irritation on the body).
* Visible signs of eczema such as dryness, roughness, or irritation on at least one part of the body at the time of enrollment.
* Willing to use Rejuvaskin Eczema Body Wash once daily as their primary body cleanser for 4 consecutive weeks.
* Willing to use Rejuvaskin Skin Recovery Cream once daily after using the - Rejuvaskin body cleanser for 4 consecutive weeks.
* Willing to maintain their current diet, skincare routine (aside from substitution of body wash and skin cream), and lifestyle habits for the study duration.
* Willing and able to take standardized photographs of an affected body area at Baseline and Week 4 using a personal smartphone.
* Able to read, understand, and complete questionnaires in English.
* Resides in the United States with a valid shipping address.
* Willing to provide informed consent and comply with all study procedures
Exclusion Criteria:
* Known allergy or sensitivity to any ingredient in the study product.
* Currently pregnant, breastfeeding, or planning to become pregnant during the study period.
* Active, severe skin condition on the body requiring prescription topical or systemic treatment (e.g., active severe atopic dermatitis flare under medical care, active infection at intended application sites).
* Currently using prescription topical corticosteroids, calcineurin inhibitors, or other prescription topical eczema treatments on the body, or initiation of such treatment planned during the study.
* Currently participating in another clinical or skincare research study, or planning to enroll during this study's duration. (
Primary outcome measure(s)
- Change from Baseline in Self-Reported Skin Dryness — Baseline to Week 4
Mean change in self-reported dryness measured via a structured self-report questionnaire administered through the Citruslabs platform
- Change from Baseline in Self-Reported Skin Roughness — Baseline to Week 4
Mean change in self-reported roughness measured via a structured self-report questionnaire administered through the Citruslabs platform
- Change from Baseline in Self-Reported Skin Itch — Baseline to Week 4
Mean change in self-reported itch measured via a structured self-report questionnaire administered through the Citruslabs platform
- Change from Baseline in Self-Reported Skin Irritation — Baseline to Week 4
Mean change in self-reported irritation measured via a structured self-report questionnaire administered through the Citruslabs platform
- Change from Baseline in Self-Reported Skin Discomfort — Baseline to Week 4
Mean change in self-reported discomfort measured via a structured self-report questionnaire administered through the Citruslabs platform
Trial sites (1)
| Facility | City | Region | Status |
|---|
| Citruslabs |
Las Vegas |
Nevada |
|